Artiva Biotherapeutics Inc (ARTV) Quarterly Institutional 13F Update (Q2 2026)

ARTV ranks #5256 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ARTV is a disclosed holding of Andreas Halvorsen (Viking Global Investors), one of the tracked superinvestors on AlphaSMO — it makes up 0.1% of that fund's own 13F portfolio.

ARTV is a top-conviction position for 5AM Venture Management, LLC — at 7.9% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in ARTV belongs to Ra Capital Management, L.p., but the position matters far more to 5AM Venture Management, LLC, who has 7.9% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

ARTV is down 3.5% today, but institutions show net buying of $235.8M this quarter — a divergence between today's price move and the underlying institutional flow.

ARTV reported a net loss of $90.8M over the trailing twelve months.

• Not yet profitable — net loss of $90.8M over the trailing twelve months
• Net income declined year over year, from -$75.1M to -$90.8M
• Operating cash flow was negative, using $76.8M in cash
• Current ratio of 8.61x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.19x equity — within a conventional range